Your gut bugs may hold the key to lung cancer therapy

NCT ID NCT04711330

Ongoing Knowledge-focused Sponsor: Leiden University Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether bacteria in the gut and throat can predict how well stage III lung cancer patients respond to the immunotherapy drug durvalumab after chemoradiation. Researchers will collect stool, throat swabs, and breath samples from 126 participants to see if these microbes can forecast treatment success or side effects. The goal is to find a non-invasive way to personalize treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab (immunotherapy)
What this could lead to: If successful, this could lead to a simple stool or throat swab test to predict which patients will benefit from durvalumab and who might experience side effects.
What could go wrong: This is an observational study, not a treatment trial. The microbiome analysis is exploratory, and results may not lead to a reliable test. The study is also relatively small (126 participants).

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNOTHERAPY NON-SMALL CELL LUNG CANCER STAGE III

Contacts and locations

Locations

Ingel Demedts

Roeselare, B8800, Belgium
Kristof Cuppens

Hasselt, Flanders, 3500, Belgium
Leiden University Medical center

Leiden, 2333ZA, Netherlands
Lynn Decoster

Turnhout, B2300, Belgium
Netherlands Cancer Institute

Amsterdam, 1066CX, Netherlands
Piet Verkouteren

Aalst, B-9300, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.